Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Revenues, net $ 24,200,000 $ 9,472,000 $ 100,824,000 $ 33,885,000
Cost of revenues 12,227,000 5,495,000 41,453,000 16,515,000
Gross profit 11,973,000 3,977,000 59,371,000 17,370,000
Operating expenses:        
Diagnostic expenses 2,398,000 1,478,000 8,869,000 6,117,000
General and administration 7,512,000 5,938,000 21,643,000 14,713,000
Research and development 110,000 208,000 174,000 416,000
Total operating expenses 10,020,000 7,624,000 30,686,000 21,246,000
Income (loss) from operations 1,953,000 (3,647,000) 28,685,000 (3,876,000)
Interest income, net 25,000 230,000 123,000 531,000
Interest expense (201,000) (296,000) (635,000) (870,000)
Change in fair value of investment securities (265,000) (76,000) (101,000)
Income (loss) from operations before income taxes 1,777,000 (3,978,000) 28,097,000 (4,316,000)
Income tax expense (809,000) (7,190,000)
Income (loss) from operations after income taxes 968,000 (3,978,000) 20,907,000 (4,316,000)
Net income (loss) 968,000 (3,978,000) 20,907,000 (4,316,000)
Other comprehensive loss:        
Unrealized loss on marketable debt securities (51,000) (33,000) (112,000) (111,000)
Total comprehensive income $ 917,000 $ (4,011,000) $ 20,795,000 $ (4,427,000)
Earnings (loss) per share:        
Basic $ 0.06 $ (0.26) $ 1.33 $ (0.29)
Diluted $ 0.06 $ (0.26) $ 1.10 $ (0.29)
Weighted average common shares outstanding:        
Basic 15,898 15,439 15,712 15,055
Diluted 20,248 15,439 19,504 15,055